Clinical trial
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma…
NCT00384150 · Biogen, Industry · Terminated
Key facts
| NCT number | NCT00384150 |
|---|---|
| Title | Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) |
| Official title | A Phase III, Open-Label, Multicenter, Single-Arm, Retreatment Study of Galiximab in Combination With Rituximab for Subjects With Relapsed, Follicular Non-Hodgkin's Lymphoma Who Previously Responded on Study 114-NH-301 |
| Lead sponsor | Biogen, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin's |
| Intervention type | Drug |
| Interventions | galiximab in combination with rituximab |
| Enrollment | 16 |
| Start date | Nov 1, 2007 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Oct 5, 2006 |
| Last update posted | Nov 26, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: